To investigate the potential of ethylenediaminetetraacetic acid (EDTA) as an adjunct to vancomycin in enhancing the efficacy against vancomycin-intermediate Staphylococcus aureus (VISA) infections.
Key Findings:
VISA exhibited downregulation of Krebs cycle enzymes and genes associated with resistance to iron and ROS-mediated killing under physiological conditions.
EDTA, alone or with vancomycin, improved H2O2-mediated killing compared to vancomycin alone.
The combination of EDTA and vancomycin enhanced neutrophil killing of VISA more effectively than either treatment alone.
In vivo, EDTA enhanced vancomycin activity against VISA.
Interpretation:
EDTA potentiates the efficacy of vancomycin against VISA by enhancing susceptibility to ROS and neutrophil-mediated killing, targeting mechanisms that allow staphylococci to evade host defenses.
Limitations:
The study primarily focuses on a single VISA strain, which may limit the generalizability of the findings.
Further research is needed to explore the clinical applicability of EDTA in diverse patient populations.
Conclusion:
EDTA shows promise as a therapeutic adjunct to enhance vancomycin efficacy against VISA, addressing critical challenges in treating antibiotic-tolerant staphylococcal infections.
